MSD’s Keytruda hits rare snag, floundering in confirmatory trial

The failure is particularly noteworthy because the FDA had already approved Keytruda for treatment in this indication through the accelerated approval pathway. MSD stressed that the indication will remain unchanged, but it does add another ding to the reputation of the drug.

The news only adds to the release earlier this month that MSD studies into multiple myeloma, with Keytruda in combination with Celgene’s medicines, had been put on hold due to a higher rate of death discovered in the Keytruda arm.

It only strengthens the argument that predicting certain success in the area is never a certainty, a lesson that perhaps should have been learnt after BMS’ major stumble with Opdivo as a first-line treatment for NSCLC.

MSD, for its part, has confirmed that it is currently trialling Keytruda as first-line treatment of recurrent or metastatic HNSCC, a trial that now looks ambitious with this most recent failure.

"We are encouraged by the positive impact that Keytruda has had on many cancer patients, including those with previously treated recurrent or metastatic head and neck cancer, and we remain confident that Keytruda is an important therapy for this difficult-to-treat cancer," said Roger Dansey, Senior Vice President and Therapeutic area Head, MSD Research Laboratories. "We look forward to sharing the comprehensive data analysis from KEYNOTE-040 with the scientific community at an upcoming medical meeting."

As mentioned by Dansey, the finer details of the trial are yet to be revealed. However, MSD did not have any difficulty in finding other positives for Keytruda, as it received recommendation for expanded of approval of the therapy in urothelial carcinoma in Europe.

The CHMP recommended the drug for patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy and I patients who are not eligible for cisplatin-containing chemotherapy. A final decision is expected in the third quarter of this year.